Found 8 Adenocarcinoma trials
A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 04223: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
A Multicenter Randomized Controlled Trial of Surveillance vs. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia
To compare the effectiveness of two approaches for the management of BE and LGD, endoscopic surveillance and endoscopic eradication therapy (EET), using accepted clinical endpoints of neoplastic progression [high-grade dysplasia (HGD)/mucosal esophageal adenocarcinoma (EAC)/invasive EAC] as determined by a blinded central adjudication committee
REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma
Phase 1
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Phase 3
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum
Phase 1
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell …
UPCC 23222: A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This is a multi-center, open-label, single arm Phase 1b/2a study of gemcitabine and nab-paclitaxel in combination with VS-6766 and defactinib in patients with previously untreated metastatic PDAC. We would like to rely on Advarra as the IRB of record for this study.
PRECEDE
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multi-site cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked …
UPCC 18223: A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed o
This is a phase 1 first in human, dose escalation trial in subjects with advanced pancreatic cancer previously treated with 5-Fluorouacil-based Chemotherapy but never exposed to therapeutic gemcitabine.
